All In Biotech

Drug Trial Radar · NCT07622706

Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma

An Open-label, Single-arm, Phase II Clinical Study of Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Sep 3, 2026

Primary completion

Dec 30, 2029

Study completion Dec 30, 2029

Sponsor

Lead sponsor
Peking University Cancer Hospital & InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An Open-label, Single-arm, Phase II Clinical Study of Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma. The goal of this study was to evaluate the efficacy of firmonertinib neoadjuvant in patients with resectable stage II-IIIB EGFR-mutated non-small cell lung cancer (NSCLC) by major pathologic response (MPR).

Conditions

  • NSCLC
  • EGFR Positive Non-small Cell Lung Cancer
  • Neoadjuvant Therapy

Interventions

  • Firmonertinib 80mg qd oral for 8 weeks.Drug

    Participations will receive the drug treatments preoperatively: Firmonertinib 80mg qd oral for 8 weeks. Radical tumor resection will be completed 3-4 weeks after the end of drug treatment.

  • Firmonertinib 160mg qd oral for 8 weeks.Drug

    Participations will receive the drug treatments preoperatively: Firmonertinib 160mg qd oral for 8 weeks. Radical tumor resection will be completed 3-4 weeks after the end of drug treatment.

  • Firmonertinib 80mg qd oral for 16 weeks.Drug

    Participations will receive the drug treatments preoperatively: Firmonertinib 80mg qd oral for 16 weeks. Radical tumor resection will be completed 3-4 weeks after the end of drug treatment.

  • Radical resectionProcedure

    Radical resection of the tumor will be performed within 3-4 weeks after the end of treatment.

  • firmonertinib adjuvant therapyDrug

    After surgery, participations will receive the drug treatments preoperatively: Firmonertinib 80mg qd oral as adjuvant therapy for 3 years. The investigator may decide whether to add chemotherapy or to change other adjuvant treatment modalities.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Pathological Response (MPR) RateTime frame: At the time of surgery (approximately Week 12 from treatment initiation for Cohort 1 and Cohort 2, and Week 20 for Cohort 3), Assessed up to 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Cancer Hospital & Institute

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.